The 50-SMA has crossed above the 200-SMA and price is holding both, keeping the longer-term structure constructive. RSI at 43.61 is in neutral-but-soft territory, signaling the pullback is mature rather than overextended, while MACD at 0.10 under its 0.23 signal line confirms near-term momentum is still fading. The 27.44 50-SMA is the pivot: reclaiming it decisively reasserts the uptrend, while losing it opens air back toward the 200-SMA at 26.42.
$PFE
LongPfizer · Core coverage · Healthcare
Technical snapshot
as of Oct 6, 2026Chart

Daily close with 50/200-day SMA and volume · Oct 6, 2026
Latest read
From the Oct 7, 2026 Playbook →Playbook history
- Oct 7, 2026Long#5 · Long · 27.50
- Oct 6, 2026Long#5 · Long · 27.50
PFE — frequently asked
- Is PFE above its 200-day moving average?
- Yes — Pfizer ($PFE) is trading 4.10% above its 200-day moving average (around 26.42), which reflects a long-term uptrend. (Educational only, not financial advice.)
- Is PFE overbought or oversold?
- PFE's 14-day RSI is 44, which is neutral. RSI above 70 is overbought, below 30 is oversold, and in between is neutral. (Educational only, not financial advice.)
- What is PFE's RSI?
- PFE's current 14-day RSI is 44 (neutral). (Educational only, not financial advice.)
- Is PFE in an uptrend or a downtrend?
- PFE's 50-day moving average (27.44) is above its 200-day (26.42), a bullish (golden-cross) structure. (Educational only, not financial advice.)
- What is the latest read on PFE?
- Our most recent Daily Playbook reads PFE as Long (#5 · Long · 27.50). (Educational only, not financial advice.)
Get PFE signals the moment they fire
Daily Playbook reads, real-time technical alerts, and human-vetted AI analysis across the market's leaders.
Educational only. Not financial advice. Technicals are end-of-day and may lag live prices.